公开(公告)号：US4956453A

公开(公告)日：1990-09-11

申请号：US69720

申请日：1987-07-06

申请人： Michael J. Bjorn ,  Arthur E. Frankel ,  Walter J. Laird ,  David B. Ring ,  Jeffrey L. Winkelhake

发明人： Michael J. Bjorn ,  Arthur E. Frankel ,  Walter J. Laird ,  David B. Ring ,  Jeffrey L. Winkelhake

IPC分类号： A61K38/00 ,  A61K47/48 ,  C07K16/30

CPC分类号： C07K16/30 ,  A61K47/48638 ,  A61K38/00 ,  Y10S424/804 ,  Y10S424/807 ,  Y10S514/885 ,  Y10S530/808 ,  Y10S530/861 ,  Y10S530/864 ,  Y10S530/866

摘要： Immunotoxins comprising a cytotoxic moiety and an antigen binding portion selected from the group consisting of Fab, Fab' and F(ab').sub.2 fragments of a monoclonal antibody, which binds to human ovarian cancer tissue, having one of the following capabilities are claimed: cytotoxic ID.sub.50 of about 10 nM or less against human ovarian cancer cells, retardation of human ovarian cancer tumor growth in mammals, or extension of survival of a mammal carrying a human ovarian cancer tumor. Antigens or epitopes to which the monoclonal antibodies bind are identified and characterize the immunotoxins. In a preferred embodiment an immunotoxin comprising at least an antigen binding portion of a monoclonal antibody, which binds to human transferrin receptor, but does not block binding of transferrin to the receptor, is described and claimed. Immunotoxin comprising the F(ab').sub.2 region of the antitransferrin monoclonal antibody are also claimed.Methods of killing human ovarian cancer cells, retarding the growth of human ovarian cancer tumors in mammals and extending the survial of mammals carrying human ovarian cancer tumors are claimed.

摘要翻译： 要求具有下列能力之一的包含细胞毒素部分和选自Fab，Fab'和F（ab'）2结合部分的单克隆抗体结合人卵巢癌组织的抗原结合部分的免疫毒素： 对人卵巢癌细胞约10nM或更少的细胞毒性ID50，哺乳动物中人卵巢癌肿瘤生长的延迟或携带人卵巢癌肿瘤的哺乳动物的存活的延长。 识别单克隆抗体结合的抗原或表位，并表征免疫毒素。 在优选的实施方案中，描述并要求保护包含至少结合人转铁蛋白受体但不阻断转铁蛋白与受体结合的单克隆抗体的抗原结合部分的免疫毒素。 还要求保护包含抗转铁蛋白单克隆抗体的F（ab'）2区的免疫毒素。 要求杀死人类卵巢癌细胞的方法，延缓哺乳动物中人卵巢癌肿瘤的生长并延长携带人卵巢癌肿瘤的哺乳动物的存活。

公开(公告)号：US4753894A

公开(公告)日：1988-06-28

申请号：US690750

申请日：1985-01-11

申请人： Arthur E. Frankel ,  David B. Ring ,  Michael J. Bjorn

发明人： Arthur E. Frankel ,  David B. Ring ,  Michael J. Bjorn

IPC分类号： G01N33/574 ,  A61K38/00 ,  A61K39/00 ,  A61K39/395 ,  A61P35/00 ,  C07K14/005 ,  C07K14/195 ,  C07K16/00 ,  C07K16/30 ,  C07K19/00 ,  C12N5/00 ,  C12N5/10 ,  C12N5/18 ,  C12N15/00 ,  C12N15/02 ,  C12P21/00 ,  C12P21/08 ,  C12Q1/02 ,  C12R1/19 ,  C12R1/91 ,  G01N33/53 ,  G01N33/577 ,  G01N33/54

CPC分类号： C07K16/3015 ,  A61K38/00 ,  C07K2317/24 ,  C07K2317/622 ,  Y10S424/804 ,  Y10S435/948 ,  Y10S530/808 ,  Y10S530/861 ,  Y10S530/864

摘要： Murine monoclonal antibodies are prepared and characterized which bind selectively to human breast cancer cells, are IgGs or IgMs, and when conjugated to ricin A chain, exhibit a TCID 50% against at least one of MCF-7, CAMA-1, SKBR-3, or BT-20 cells of less than about 10 nM. Methods for diagnosing, monitoring, and treating human breast cancer with the antibodies or immunotoxins made therefrom are described.

摘要翻译： 制备和表征鼠单克隆抗体，其选择性结合人乳腺癌细胞，IgG或IgM，当与蓖麻毒蛋白A链缀合时，对MCF-7，CAMA-1，SKBR-3中的至少一种显示TCID为50％ ，或小于约10nM的BT-20细胞。 描述了用由其制备的抗体或免疫毒素来诊断，监测和治疗人乳腺癌的方法。

公开(公告)号：US5629197A

公开(公告)日：1997-05-13

申请号：US288981

申请日：1994-08-11

申请人： David B. Ring ,  Arthur E. Frankel ,  Michael J. Bjorn

发明人： David B. Ring ,  Arthur E. Frankel ,  Michael J. Bjorn

IPC分类号： A61K38/00 ,  C07K16/30 ,  C12N5/12 ,  C07K16/18

CPC分类号： C07K16/3015 ,  A61K38/00 ,  C07K2317/24 ,  C07K2317/622 ,  Y10S436/813 ,  Y10S530/808 ,  Y10S530/809 ,  Y10S530/864

摘要： Murine monoclonal antibodies are prepared and characterized which bind selectively to high molecular weight mucins by immunoprecipitation test and are IgGs or IgMs. Immunotoxins comprising the monoclonal antibody and cytotoxic moiety were produced.

摘要翻译： 制备和表征鼠单克隆抗体，其通过免疫沉淀试验选择性地结合高分子量粘蛋白，并且是IgG或IgM。 制备了包含单克隆抗体和细胞毒性部分的免疫毒素。

公开(公告)号：US4958009A

公开(公告)日：1990-09-18

申请号：US69867

申请日：1987-07-06

申请人： Michael J. Bjorn ,  David J. FitzGerald ,  Arthur E. Frankel ,  Walter J. Laird ,  Ira H. Pastan ,  David B. Ring ,  Mark C. Willingham ,  Jeffrey L. Windelhake

发明人： Michael J. Bjorn ,  David J. FitzGerald ,  Arthur E. Frankel ,  Walter J. Laird ,  Ira H. Pastan ,  David B. Ring ,  Mark C. Willingham ,  Jeffrey L. Windelhake

IPC分类号： C12N15/02 ,  A61K38/00 ,  A61K39/395 ,  A61K47/00 ,  A61K47/48 ,  A61P35/00 ,  C07K14/00 ,  C07K14/195 ,  C07K14/37 ,  C07K14/41 ,  C07K14/415 ,  C07K16/00 ,  C07K16/30 ,  C07K19/00 ,  C12N5/00 ,  C12N5/10 ,  C12P21/00 ,  C12P21/08 ,  C12R1/91 ,  G01N33/574 ,  G01N33/577

CPC分类号： C07K16/30 ,  A61K47/48638 ,  A61K38/00 ,  Y10S424/804 ,  Y10S424/807 ,  Y10S514/885 ,  Y10S530/808 ,  Y10S530/864

摘要： Immunotoxins comprising a cytotoxic moiety and monoclonal antibodies which bind to human ovarian cancer tissue having at least one of the following capabilities are claimed: cytotoxic ID.sub.50 of 10 nM or less against human ovarian cancer cells, retardation of human ovarian cancer tumor growth in mammals or extension of survival of a mammal carrying a human ovarian cancer tumor. Antigens to which the monoclonal antibody of the immunotoxin bind are identified and characterize the immunotoxins. Methods of killing human ovarian cancer cells, retarding the growth of human ovarian cancer tumors in mammals or extending the survival of mammals carrying human ovarian cancer tumors are claimed.

摘要翻译： 包含细胞毒素部分的免疫毒素和结合至少具有以下能力之一的人卵巢癌组织的单克隆抗体是要求保护的：针对人卵巢癌细胞的10nM或更小的细胞毒性ID50，哺乳动物或延伸中人卵巢癌肿瘤生长的延迟 携带人卵巢癌肿瘤的哺乳动物的存活。 识别免疫毒素结合的单克隆抗体的抗原并表征免疫毒素。 要求杀死人类卵巢癌细胞的方法，延缓哺乳动物中人卵巢癌肿瘤的生长或延长携带人卵巢癌肿瘤的哺乳动物的存活。

公开(公告)号：US5169774A

公开(公告)日：1992-12-08

申请号：US190778

申请日：1988-05-06

申请人： Arthur E. Frankel ,  David B. Ring ,  Walter Laird

发明人： Arthur E. Frankel ,  David B. Ring ,  Walter Laird

IPC分类号： A61K38/00 ,  C07K16/30

CPC分类号： C07K16/3015 ,  A61K38/00 ,  C07K2317/24 ,  C07K2317/622 ,  Y10S436/813 ,  Y10S530/808 ,  Y10S530/809 ,  Y10S530/864

摘要： Murine monoclonal antibodies, or fragments thereof, that bind selectively to human breast cancer cells, are IgGs or IgMs, and when conjugated to ricin A chain, exhibit a TCID 50% against at least one of MCF-7, CAMA-1, SKBR-3, or BT-20 cells of less than about 10 nM. Methods for diagnosing, monitoring, and treating human breast cancer with the antibodies or immunotoxins made therefrom are described.

摘要翻译： 与人乳腺癌细胞结合选择性的鼠单克隆抗体或其片段是IgG或IgM，当与蓖麻毒蛋白A链结合时，其对MCF-7，CAMA-1，SKBR- 3或BT-20细胞小于约10nM。 描述了用由其制备的抗体或免疫毒素来诊断，监测和治疗人乳腺癌的方法。

公开(公告)号：US4938948A

公开(公告)日：1990-07-03

申请号：US786948

申请日：1985-10-11

申请人： David B. Ring ,  Arthur E. Frankel

发明人： David B. Ring ,  Arthur E. Frankel

IPC分类号： C12N15/02 ,  A61K39/395 ,  A61K49/00 ,  A61K51/00 ,  A61K51/10 ,  A61P31/12 ,  C07K16/30 ,  C12N5/00 ,  C12N5/10 ,  C12N15/00 ,  C12P21/00 ,  C12P21/08 ,  C12R1/91 ,  G01N33/574 ,  G01N33/577

CPC分类号： A61K49/0058 ,  A61K51/10 ,  A61K51/1093 ,  C07K16/3015 ,  Y10S424/804 ,  Y10S424/807 ,  Y10S435/948 ,  Y10S530/808 ,  Y10S530/861

摘要： Hybridomas producing monoclonal antibodies suitable for imaging and diagnosis of human breast tumors and such monoclonal antibodies are claimed. The monoclonals are characterized by breast tumor binding range, breast cancer cell line range, and selectivity.Immunoimaging agents comprising the monoclonal antibody and a detectable label, either directly or indirectly conjugated to the antibody are claimed. Methods for imaging breast tumors using the immunoimaging agents are described and claimed.

摘要翻译： 要求生产适用于人乳腺肿瘤和这种单克隆抗体成像和诊断的单克隆抗体的杂交瘤。 单克隆抗体的特征在于乳腺肿瘤结合范围，乳腺癌细胞系范围和选择性。 要求包含与抗体直接或间接缀合的单克隆抗体和可检测标记的免疫成像剂。 描述和要求保护使用免疫成像剂对乳腺肿瘤成像的方法。

公开(公告)号：US4803169A

公开(公告)日：1989-02-07

申请号：US826477

申请日：1986-02-05

申请人： Peter S. Linsley ,  Vincent W. Ochs ,  Diane Horn ,  Joseph P. Brown ,  David B. Ring ,  Arthur E. Frankel

发明人： Peter S. Linsley ,  Vincent W. Ochs ,  Diane Horn ,  Joseph P. Brown ,  David B. Ring ,  Arthur E. Frankel

IPC分类号： C12N15/00 ,  C12N15/02 ,  C12P21/00 ,  C12P21/08 ,  G01N33/574 ,  G01N33/577

CPC分类号： G01N33/57415 ,  Y10S436/813

摘要： Methods are disclosed for detecting, staging and monitoring breast cancer. The methods involve determining the amount of certain antigens, designated W1 and W9, in serum via quantitative immunoassays using anti-W1 or anti-W9 monoclonal antibodies. The amount detected is compared with amounts of the antigen found in normal sera, sera from breast cancer patients of predetermined stage, or other samples of the patient's own serum, depending upon the purpose of the assay.

摘要翻译： 公开了用于检测，分期和监测乳腺癌的方法。 所述方法包括使用抗-W1或抗-W9单克隆抗体通过定量免疫测定来测定血清中某些抗原（称为W1和W9）的量。 根据测定的目的，将检测到的量与在正常血清，预定阶段的乳腺癌患者的血清或患者自身血清的其他样品中发现的抗原的量进行比较。

公开(公告)号：US07138497B2

公开(公告)日：2006-11-21

申请号：US09887853

申请日：2001-06-21

申请人： Lou L. Houston ,  David B. Ring

发明人： Lou L. Houston ,  David B. Ring

IPC分类号： C07K16/28 ,  C07K16/30 ,  C07K16/32

CPC分类号： C07K16/32 ,  A61K2039/505 ,  C07K16/22 ,  C07K16/30 ,  C07K16/3015 ,  C07K16/3069 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/622 ,  C07K2319/00 ,  C07K2319/02 ,  C07K2319/33 ,  C07K2319/55

摘要： Disclosed is a formulation for targeting an epitope on an antigen expressed in a mammal. The formulation comprises a pharmaceutically acceptable carrier together with a dimeric biosynthetic construct for binding at least one preselected antigen. The biosynthetic construct contains two polypeptide chains, each of which define single-chain Fv (sFv) binding proteins and have C-terminal tails that facilitate the crosslinking of two sFv polypeptides. The resulting dimeric constructs have a conformation permitting binding of a said preselected antigen by the binding site of each said polypeptide chain when administered to said mammal. The formulation has particular utility in in vivo imaging and drug targeting experiments.

公开(公告)号：US5837846A

公开(公告)日：1998-11-17

申请号：US461386

申请日：1995-06-05

申请人： James S. Huston ,  L. L. Houston ,  David B. Ring ,  Hermann Oppermann

发明人： James S. Huston ,  L. L. Houston ,  David B. Ring ,  Hermann Oppermann

IPC分类号： C12N15/09 ,  A61K39/395 ,  A61K49/00 ,  A61K51/00 ,  A61K51/08 ,  A61P35/00 ,  C07H21/04 ,  C07K16/22 ,  C07K16/28 ,  C07K16/30 ,  C07K16/32 ,  C07K16/46 ,  C07K19/00 ,  C12N1/15 ,  C12N1/19 ,  C12N1/21 ,  C12N5/10 ,  C12N15/13 ,  C12N15/62 ,  C12N15/66 ,  C12P21/02 ,  C12P21/08 ,  C12R1/19

CPC分类号： C07K16/32 ,  C07K16/22 ,  C07K16/30 ,  C07K16/3015 ,  C07K16/3069 ,  A61K2039/505 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/622 ,  C07K2319/00 ,  C07K2319/02 ,  C07K2319/33 ,  C07K2319/55

摘要： Disclosed is a formulation for targeting an epitope on an antigen expressed in a mammal. The formulation comprises a pharmaceutically acceptable carrier together with a dimeric biosynthetic construct for binding at least one preselected antigen. The biosynthetic construct contains two polypeptide chains, each of which define single-chain Fv (sFv) binding proteins and have C-terminal tails that facilitate the crosslinking of two sFv polypeptides. The resulting dimeric constructs have a conformation permitting binding of a said preselected antigen by the binding site of each said polypeptide chain when administered to said mammal. The formulation has particular utility in in vivo imaging and drug targeting experiments.

公开(公告)号：US4569915A

公开(公告)日：1986-02-11

申请号：US583166

申请日：1984-02-24

申请人： David B. Ring

发明人： David B. Ring

IPC分类号： C12N9/04 ,  C12N1/14 ,  C12P19/22 ,  C12R1/645

CPC分类号： C12N9/0006 ,  C12R1/645 ,  Y10S435/911

摘要： A P. obtusus strain AU124 having the identifying characteristics of NRRL No. 15595, the strain produces high levels of pyranose-2-oxidase.

摘要翻译： 具有NRRL No.15595的鉴定特征的P. obtusus菌株AU124，该菌株产生高水平的吡喃糖-2-氧化酶。